Ping An Enhances Recruitment Experience with “Ping An Talent” AI System
HONG KONG and SHANGHAI, March 4, 2025 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An", "the Company" or the "Group" HKEX: 2318 / 82318; SSE: 601318) recently launched its 2025 Spring Campus Recruitment offering over 2,000 positions, highlighted by Ping An's self-developed "Ping An Talent" recruitment system. This platform integrates AI-driven job matching, AI interviews, and AI...
Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®
STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively, The FDA approval is based on robust clinical evidence, which show no clinically meaningful differences from the reference products With the FDA approval of STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)...
Chulalongkorn University Unveils Exoskeleton Wheelchair to Aid Mobility
BANGKOK, March 4, 2025 /PRNewswire/ -- Chulalongkorn University has introduced the Exoskeleton Wheelchair, an innovative robotic suit designed to help people with disabilities stand, walk, and move more independently. The breakthrough was developed by Assoc. Prof. Dr. Ronnapee Chaichaowarat from the Faculty of Engineering, aiming to improve mobility beyond traditional wheelchairs. Chulalongkorn University Unveils Exoskeleton...
HKBU clinches four gold medals at the 15th International Invention Fair in the Middle East
HONG KONG, March 4, 2025 /PRNewswire/ -- Hong Kong Baptist University (HKBU) won four gold medals at the 15th International Invention Fair in the Middle East (IIFME) held in Kuwait from 16 to 19 February. It was the first time that HKBU participated in the event. Four HKBU inventions are awarded gold medals at the 15th International Invention Fair in...
DeepQure Advances Global Clinical Trials for Innovative RDN Technology
SEOUL, South Korea, March 4, 2025 /PRNewswire/ -- Breaking Barriers in Hypertension TreatmentDeepQure Inc., a pioneering medical device startup, is revolutionizing the treatment of resistant hypertension with its innovative extravascular (laparoscopic approach) renal denervation (RDN) device, HyperQureTM. Unlike traditional catheter-based RDN systems, HyperQureTM employs a novel approach to achieve more effective and precise sympathetic nerve ablation, minimizing the...
Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction (“double chin”)
REROVOT, Israel, March 4, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation in China for the treatment of fat reduction in the submental area. Submental fat (SMF) reduction is the first indication for RZL-012 among many potential aesthetic focal fat reduction treatments for body shaping....
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe - EffiX™ delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for...
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody
SUZHOU, China, March 4, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient has been successfully dosed in the global multicenter Phase I clinical trial of its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, with no infusion reactions or other adverse events observed. This...
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an overview on...
Apply Now for The Sigourney Award-2025 Honoring Outstanding Psychoanalytic Work Around The World
SAN FRANCISCO, March 3, 2025 /PRNewswire/ -- The Sigourney Award Trust is accepting applications and nominations for The Sigourney Award-2025 now through July 31st. The prestigious, wholly independent prize celebrates 35 years of recognizing work by individuals, teams, and organizations from around the world who have advanced psychoanalytic thought, principles and practice....
